NYSE:WST - West Pharmaceutical Services Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $310.00
  • Forecasted Upside: -13.31 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
▲ +5.3 (1.50%)

This chart shows the closing price for WST by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New West Pharmaceutical Services Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for WST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for WST

Analyst Price Target is $310.00
▼ -13.31% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for West Pharmaceutical Services in the last 3 months. The average price target is $310.00, with a high forecast of $350.00 and a low forecast of $280.00. The average price target represents a -13.31% upside from the last price of $357.59.

This chart shows the closing price for WST for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in West Pharmaceutical Services. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/9/2020KeyCorpInitiated CoverageOverweight$350.00High
10/13/2020StephensInitiated CoverageEqual Weight$300.00High
7/21/2020Bank of AmericaUpgradeNeutral ➝ Buy$280.00Low
4/24/2020Bank of AmericaUpgradeUnderperform ➝ Neutral$145.00 ➝ $200.00High
12/12/2019Bank of AmericaDowngradeNeutral ➝ Underperform$135.00Medium
7/26/2019Bank of AmericaUpgradeUnderperform ➝ NeutralHigh
5/1/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$122.00Medium
4/23/2019William BlairInitiated CoverageOutperform ➝ Outperform$112.16Medium
4/25/2018Bank of AmericaDowngradeNeutral ➝ Underperform$85.00High
1/24/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$110.00Low
10/27/2017Wells Fargo & CompanyBoost Price TargetOutperform$105.00 ➝ $112.00N/A
10/17/2017Bank of AmericaDowngradeBuy ➝ Neutral$98.00N/A
10/3/2017StephensInitiated CoverageEqual ➝ Equal Weight$99.00Medium
9/15/2017Jefferies Financial GroupUpgradeHold ➝ Buy$96.00 ➝ $115.00High
6/8/2017Jefferies Financial GroupReiterated RatingHold$90.00Low
4/28/2017Jefferies Financial GroupReiterated RatingHold$82.00 ➝ $90.00Low
2/21/2017Jefferies Financial GroupReiterated RatingHold$82.00N/A
1/24/2017Jefferies Financial GroupBoost Price TargetHold$76.00 ➝ $82.00N/A
12/23/2016Janney Montgomery ScottReiterated RatingBuyN/A
10/28/2016Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformN/A
9/26/2016Janney Montgomery ScottReiterated RatingBuy ➝ Fair Value$90.00 ➝ $72.55N/A
9/21/2016Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformN/A
8/4/2016Jefferies Financial GroupReiterated RatingHoldN/A
7/29/2016Jefferies Financial GroupBoost Price TargetHold$67.00 ➝ $77.00N/A
(Data available from 6/21/2016 forward)
West Pharmaceutical Services logo
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Read More

Today's Range

Now: $357.59
Low: $349.98
High: $358.34

50 Day Range

MA: $330.97
Low: $296.94
High: $352.29

52 Week Range

Now: $357.59
Low: $213.02
High: $358.34


286,902 shs

Average Volume

441,415 shs

Market Capitalization

$26.40 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of West Pharmaceutical Services?

The following equities research analysts have issued reports on West Pharmaceutical Services in the last year: Bank of America Co., KeyCorp, Stephens, and Zacks Investment Research.
View the latest analyst ratings for WST.

What is the current price target for West Pharmaceutical Services?

3 Wall Street analysts have set twelve-month price targets for West Pharmaceutical Services in the last year. Their average twelve-month price target is $310.00, suggesting a possible downside of 12.0%. KeyCorp has the highest price target set, predicting WST will reach $350.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $280.00 for West Pharmaceutical Services in the next year.
View the latest price targets for WST.

What is the current consensus analyst rating for West Pharmaceutical Services?

West Pharmaceutical Services currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe WST will outperform the market and that investors should add to their positions of West Pharmaceutical Services.
View the latest ratings for WST.

What other companies compete with West Pharmaceutical Services?

How do I contact West Pharmaceutical Services' investor relations team?

West Pharmaceutical Services' physical mailing address is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. The medical instruments supplier's listed phone number is 610-594-2900 and its investor relations email address is [email protected] The official website for West Pharmaceutical Services is www.westpharma.com.